{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:05Z","timestamp":1790166185136,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.clml.2012.01.005","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T18:41:14Z","timestamp":1331923274000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Eduardo","family":"Cervera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Candelaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"L\u00f3pez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Labardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gonzalez-Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taja-Chayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gordillo-Bastidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Due\u00f1as-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.01.005_bib1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.01.005_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.01.005_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib6","series-title":"Cancer Medicine","first-page":"1582","article-title":"Chronic myeloid leukemia","author":"Cortes","year":"2010"},{"key":"10.1016\/j.clml.2012.01.005_bib7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.01.005_bib8","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective bcr-abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib9","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.01.005_bib11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.01.005_bib12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","article-title":"Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.005_bib13","first-page":"1333","article-title":"Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance","volume":"9","author":"Marcucci","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.005_bib14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.01.005_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.biocel.2007.10.001","article-title":"Overcoming kinase resistance in chronic myeloid leukemia","volume":"40","author":"Lee","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2012.01.005_bib16","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clml.2012.01.005_bib17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr\u2013Abl independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2012.01.005_bib18","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr\u2013Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.01.005_bib19","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib induced apoptosis of Bcr\u2013Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib20","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.005_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-4-10","article-title":"Hydralazine target: from blood vessels to the epigenome","volume":"4","author":"Arce","year":"2006","journal-title":"J Translat Med"},{"key":"10.1016\/j.clml.2012.01.005_bib22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/cmdc.200900017","article-title":"Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase","volume":"1","author":"Singh","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.clml.2012.01.005_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2012.01.005_bib24","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer","volume":"1","author":"Arce","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clml.2012.01.005_bib25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.01.005_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","article-title":"Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome","volume":"90","author":"Candelaria","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.01.005_bib27","first-page":"386","article-title":"Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer","volume":"31","author":"Candelaria","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clml.2012.01.005_bib28","first-page":"1507","article-title":"A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer","volume":"28","author":"Coronel","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2012.01.005_bib29","first-page":"657579","article-title":"Response to hydralazine-valproate in a patient with mycosis fungoides","volume":"2010","author":"Due\u00f1as-Gonzalez","year":"2010","journal-title":"Med Case Report Med"},{"key":"10.1016\/j.clml.2012.01.005_bib30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.01.005_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk' chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European LeukemiaNet","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.01.005_bib33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the world Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important change","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5414\/CP201526","article-title":"Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype","volume":"49","author":"Gonzalez-Fierro","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2012.01.005_bib35","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"San Jos\u00e9-Eneriz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2012.01.005_bib36","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","article-title":"Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance","volume":"21","author":"Li","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.01.005_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11010-010-0683-3","article-title":"Decitabine-induced apoptosis is derived by puma and noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA","volume":"350","author":"Brodsk\u00e1","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clml.2012.01.005_bib38","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.005_bib39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2174\/092986711795496791","article-title":"Epigenetically-targeted therapies for the treatment of hematological malignancies","volume":"18","author":"Georgiou","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clml.2012.01.005_bib40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.01.005_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/157488408785747656","article-title":"Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients","volume":"3","author":"Pursche","year":"2008","journal-title":"Curr Clin Pharmacologist"},{"key":"10.1016\/j.clml.2012.01.005_bib42","first-page":"399","article-title":"Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma","volume":"25","author":"De la Cruz-Hern\u00e1ndez","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2012.01.005_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.leukres.2011.01.033","article-title":"Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid","volume":"35","author":"Buchi","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.01.005_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2012.01.005_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V114.22.861.861","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors\u2014results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.005_bib46","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0145-2126(03)00094-8","article-title":"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase","volume":"27","author":"Giles","year":"2003","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:56Z","timestamp":1761870116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S2152265012000067"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}